A Double-Blind, Randomized, Cross-Over Design, Phase 1 Pharmacodynamic Study to Investigate the Effect of Different Formulations of AZD3355 for the Development of Paresthesiae After Dosing in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2010
At a glance
- Drugs Lesogaberan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Adverse reactions
- Sponsors AstraZeneca
- 02 Dec 2010 Actual end date changed from Jul 2008 to Jun 2008 as reported by ClinicalTrials.gov.
- 11 Aug 2008 Status changed from active, no longer recruiting to completed.
- 24 Jun 2008 New trial record.